495 related articles for article (PubMed ID: 10742155)
1. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
[TBL] [Abstract][Full Text] [Related]
2. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.
Bessen D; Fischetti VA
J Immunol; 1990 Aug; 145(4):1251-6. PubMed ID: 1696296
[TBL] [Abstract][Full Text] [Related]
3. Mapping a conserved conformational epitope from the M protein of group A streptococci.
Relf WA; Cooper J; Brandt ER; Hayman WA; Anders RF; Pruksakorn S; Currie B; Saul A; Good MF
Pept Res; 1996; 9(1):12-20. PubMed ID: 8727479
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
5. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
Bronze MS; Courtney HS; Dale JB
J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
[TBL] [Abstract][Full Text] [Related]
6. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.
Georgousakis MM; Hofmann A; Batzloff MR; McMillan DJ; Sriprakash KS
Vaccine; 2009 Nov; 27(48):6799-806. PubMed ID: 19729086
[TBL] [Abstract][Full Text] [Related]
7. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.
Vohra H; Dey N; Gupta S; Sharma AK; Kumar R; McMillan D; Good MF
Res Microbiol; 2005 May; 156(4):575-82. PubMed ID: 15862457
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
9. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
10. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
11. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
12. Recombinant tetravalent group A streptococcal M protein vaccine.
Dale JB; Chiang EY; Lederer JW
J Immunol; 1993 Aug; 151(4):2188-94. PubMed ID: 8345202
[TBL] [Abstract][Full Text] [Related]
13. Surface-exposed conserved region of the streptococcal M protein induces antibodies cross-reactive with denatured forms of myosin.
Vashishtha A; Fischetti VA
J Immunol; 1993 May; 150(10):4693-701. PubMed ID: 8482854
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
15. Prospects for a group A streptococcal vaccine.
McMillan DJ; Chhatwal GS
Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
[TBL] [Abstract][Full Text] [Related]
16. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
Olive C; Clair T; Yarwood P; Good MF
Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
[TBL] [Abstract][Full Text] [Related]
17. Induction of a mucosal immune response to the streptococcal M protein by intramuscular administration of a PADRE-ASREAK peptide.
Pamonsinlapatham P; Decroix N; Mihaila-Amrouche L; Bouvet A; Bouvet JP
Scand J Immunol; 2004 May; 59(5):504-10. PubMed ID: 15140061
[TBL] [Abstract][Full Text] [Related]
18. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies.
Pruksakorn S; Galbraith A; Houghten RA; Good MF
J Immunol; 1992 Oct; 149(8):2729-35. PubMed ID: 1383324
[TBL] [Abstract][Full Text] [Related]
19. Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein.
Kraus W; Haanes-Fritz E; Cleary PP; Seyer JM; Dale JB; Beachey EH
J Immunol; 1987 Nov; 139(9):3084-90. PubMed ID: 2444650
[TBL] [Abstract][Full Text] [Related]
20. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]